Table 4.
Characteristics of microscopy-confirmed Plasmodium falciparum infections and those eligible for clearance follow-up
| Characteristic | Baseline | Follow-up | ||||
|---|---|---|---|---|---|---|
| All cohort positive | Clearance eligible* | Day 3 | Day 7 | Month 1 | Month 2 | |
| Baseline parasite density, mean pa/µL (95% CI) | 1,795 (1,209–2,382) | 1,861 (1,238–2,485) | 2,023 (1,270–2,777) | 2,213 (1,360–3,066) | 1,855 (1,113–2,597) | 1,518 (1,055–1,982) |
| Gender, % (95% CI) | ||||||
| Female | 54.8 (42.2–66.9) | 55.2 (42.0–67.6) | 57.8 (42.7–71.5) | 61.5 (45.1–75.7) | 56.5 (41.7–70.3) | 62.5 (47.8–75.2) |
| Age category (years), % (95% CI) | ||||||
| < 5 | 16.1 (8.8–27.7) | 15.5 (8.2–27.5) | 8.9 (3.3–21.9) | 10.3 (3.8–25.0) | 17.4 (8.8–31.5) | 14.6 (7.0–28.0) |
| 5–15 | 56.5 (43.7–68.4) | 58.6 (45.4–70.7) | 66.7 (51.4–79.1) | 69.2 (52.7–82.0) | 58.7 (43.7–72.2) | 60.4 (45.7–73.4) |
| > 15 | 27.4 (17.6–40.0) | 25.9 (16.1–38.9) | 24.4 (13.9–39.4) | 20.5 (10.4–36.5) | 23.9 (13.5–38.7) | 25.0 (14.6–39.5) |
| MDA treatment group, % (95% CI) | ||||||
| Focal MDA | 59.7 (46.9–71.3) | 56.9 (43.7–69.2) | 55.6 (40.6–69.6) | 53.8 (37.8–69.1) | 50.0 (35.6–64.4) | 58.3 (43.7–71.6) |
| Mass drug administration | 40.3 (28.7–53.1) | 43.1 (30.8–56.3) | 44.4 (30.4–59.4) | 46.2 (30.9–62.2) | 50.0 (35.6–64.4) | 41.7 (28.4–56.3) |
| Total, N | 62 | 58 | 45 | 39 | 46 | 48 |
Distribution of characteristics across time points was not significantly different by Pearson’s chi-square test.
*
Participants eligible for analysis if confirmed positive by microscopy and reported as receiving treatment at baseline.